Record Q2 revenue; ex-US surpasses US as FY28 ambition stays intact

Management guided margin improvementManagement guided margin pressureOrder pipeline disclosedMulti-year targets disclosedCFO laid out a debt-reduction roadmapInvestor Communications View source PDF Explain this filing

STAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.4%Reaction day

₹1030.00

prior close

₹1040.00

announcement price

After-mkt

timing

Nifty Microcap 250market+0.3%-0.7% vs market

Pharmaceuticals peers, median of 170sector+0.1%-0.6% vs sector

On the reaction day the stock moved 0.7 pts less than Nifty Microcap 250 and 0.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.3

10m

-1.8

15m

-2.4

30m

-2.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.4+0.3-0.7+0.1-0.6

Next day

-1.4+2.4-3.8+1.1-2.5

-2.0+3.6-5.6+2.0-4.1

-3.0pendingpending+1.9-4.8

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q2 FY27 revenue rose 17% year on year to ₹14,297 million, a record, as ex-US revenue grew 31% and exceeded US revenue for the first time. EBITDA rose 8% to ₹2,509 million, but margin fell to 17.6% from 19.0% on higher material and freight costs. Management expects H2 to be stronger, the FY28 growth ambition to remain intact, and the US revenue target of $375 million to be reached slightly beyond FY28.

Likely market impact

Record sales and ex-US growth support the outlook, but costs and working capital are risks. Debt burden should ease as inventory normalises.